Search Results - "Longshore, John"

Implementing TMB measurement in clinical practice: considerations on assay requirements by Büttner, Reinhard, Longshore, John W, López-Ríos, Fernando, Merkelbach-Bruse, Sabine, Normanno, Nicola, Rouleau, Etienne, Penault-Llorca, Frédérique

“…Clinical evidence demonstrates that treatment with immune checkpoint inhibitor immunotherapy agents can have considerable benefit across multiple tumours…”
Get full text

Point: Comprehensive Molecular Testing Functions Best in a Consolidated Model by Longshore, John W

Get full text

Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer by Büttner, Reinhard, Gosney, John R, Skov, Birgit Guldhammer, Adam, Julien, Motoi, Noriko, Bloom, Kenneth J, Dietel, Manfred, Longshore, John W, López-Ríos, Fernando, Penault-Llorca, Frédérique, Viale, Giuseppe, Wotherspoon, Andrew C, Kerr, Keith M, Tsao, Ming-Sound

“…Purpose Three programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors are currently approved for treatment of non-small-cell lung cancer (NSCLC)…”
Get full text

Comprehensive Molecular Testing Functions Best in a Consolidated Model by Longshore, John W

“…A significant advantage of the core molecular laboratory is often the expansion of testing to multiple shifts, which may lead to a highly efficient delivery of…”
Get full text

The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee by Sholl, Lynette M, Hirsch, Fred R, Hwang, David, Botling, Johan, Lopez-Rios, Fernando, Bubendorf, Lukas, Mino-Kenudson, Mari, Roden, Anja C, Beasley, Mary Beth, Borczuk, Alain, Brambilla, Elisabeth, Chen, Gang, Chou, Teh-Ying, Chung, Jin-Haeng, Cooper, Wendy A, Dacic, Sanja, Lantuejoul, Sylvie, Jain, Deepali, Lin, Dongmei, Minami, Yuko, Moreira, Andre, Nicholson, Andrew G, Noguchi, Masayuki, Papotti, Mauro, Pelosi, Giuseppe, Poleri, Claudia, Rekhtman, Natasha, Tsao, Ming-Sound, Thunnissen, Erik, Travis, William, Yatabe, Yasushi, Yoshida, Akihiko, Daigneault, Jillian B, Zehir, Ahmet, Peters, Solange, Wistuba, Ignacio I, Kerr, Keith M, Longshore, John W

“…Immune checkpoint inhibitor (ICI) therapies have revolutionized the management of patients with NSCLC and have led to unprecedented improvements in response…”
Get more information

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project by Hirsch, Fred R, McElhinny, Abigail, Stanforth, Dave, Ranger-Moore, James, Jansson, Malinka, Kulangara, Karina, Richardson, William, Towne, Penny, Hanks, Debra, Vennapusa, Bharathi, Mistry, Amita, Kalamegham, Rasika, Averbuch, Steve, Novotny, James, Rubin, Eric, Emancipator, Kenneth, McCaffery, Ian, Williams, J Andrew, Walker, Jill, Longshore, John, Tsao, Ming Sound, Kerr, Keith M

“…The Blueprint Programmed Death Ligand 1 (PD-L1) Immunohistochemistry (IHC) Assay Comparison Project is an industrial-academic collaborative partnership to…”
Get more information

Performance of the cobas EZH2 mutation test on clinical samples from non-Hodgkin lymphoma patients by Shyu, Johnny Y, Schlag, Peter A, Karwowska, Sylwia M, Manohar, Chitra F, Truong, Huan M, Longshore, John W, Zhang, Guili

“…To present the technical verification and clinical validation of the companion diagnostic assay, cobas® EZH2 Mutation Test (cobas EZH2 Test), targeting…”
Get full text

PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee by Lantuejoul, Sylvie, Sound-Tsao, Ming, Cooper, Wendy A, Girard, Nicolas, Hirsch, Fred R, Roden, Anja C, Lopez-Rios, Fernando, Jain, Deepali, Chou, Teh-Ying, Motoi, Noriko, Kerr, Keith M, Yatabe, Yasushi, Brambilla, Elisabeth, Longshore, John, Papotti, Mauro, Sholl, Lynette M, Thunnissen, Erik, Rekhtman, Natasha, Borczuk, Alain, Bubendorf, Lukas, Minami, Yuko, Beasley, Mary Beth, Botling, Johan, Chen, Gang, Chung, Jin-Haeng, Dacic, Sanja, Hwang, David, Lin, Dongmei, Moreira, Andre, Nicholson, Andrew G, Noguchi, Masayuki, Pelosi, Giuseppe, Poleri, Claudia, Travis, William, Yoshida, Akihiko, Daigneault, Jillian B, Wistuba, Ignacio I, Mino-Kenudson, Mari

“…The recent development of immune checkpoint inhibitors (ICIs) has led to promising advances in the treatment of patients with NSCLC and SCLC with advanced or…”
Get more information

Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays by Fisher, Kevin E., MD, PhD, Cohen, Cynthia, MD, Siddiqui, Momin T., MD, Palma, John F., PhD, Lipford, Edward H., MD, Longshore, John W., PhD

“…Summary Malignant melanoma patients require BRAF mutation testing prior to initiating BRAF inhibitor therapy. Molecular testing remains the diagnostic gold…”
Get full text

A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee by Moreira, Andre L, Ocampo, Paolo S S, Xia, Yuhe, Zhong, Hua, Russell, Prudence A, Minami, Yuko, Cooper, Wendy A, Yoshida, Akihiko, Bubendorf, Lukas, Papotti, Mauro, Pelosi, Giuseppe, Lopez-Rios, Fernando, Kunitoki, Keiko, Ferrari-Light, Dana, Sholl, Lynette M, Beasley, Mary Beth, Borczuk, Alain, Botling, Johan, Brambilla, Elisabeth, Chen, Gang, Chou, Teh-Ying, Chung, Jin-Haeng, Dacic, Sanja, Jain, Deepali, Hirsch, Fred R, Hwang, David, Lantuejoul, Sylvie, Lin, Dongmei, Longshore, John W, Motoi, Noriko, Noguchi, Masayuki, Poleri, Claudia, Rekhtman, Natasha, Tsao, Ming-Sound, Thunnissen, Erik, Travis, William D, Yatabe, Yasushi, Roden, Anja C, Daigneault, Jillian B, Wistuba, Ignacio I, Kerr, Keith M, Pass, Harvey, Nicholson, Andrew G, Mino-Kenudson, Mari

“…A grading system for pulmonary adenocarcinoma has not been established. The International Association for the Study of Lung Cancer pathology panel evaluated a…”
Get more information

X Chromosome–Inactivation Patterns of 1,005 Phenotypically Unaffected Females by Amos-Landgraf, James M., Cottle, Amy, Plenge, Robert M., Friez, Mike, Schwartz, Charles E., Longshore, John, Willard, Huntington F.

“…X-chromosome inactivation is widely believed to be random in early female development and to result in a mosaic distribution of cells, approximately half with…”
Get full text

The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC by Mino-Kenudson, Mari, Le Stang, Nolwenn, Daigneault, Jillian B, Nicholson, Andrew G, Cooper, Wendy A, Roden, Anja C, Moreira, Andre L, Thunnissen, Erik, Papotti, Mauro, Pelosi, Giuseppe, Motoi, Noriko, Poleri, Claudia, Brambilla, Elisabeth, Redman, Mary, Jain, Deepali, Dacic, Sanja, Yatabe, Yasushi, Tsao, Ming Sound, Lopez-Rios, Fernando, Botling, Johan, Chen, Gang, Chou, Teh-Ying, Hirsch, Fred R, Beasley, Mary Beth, Borczuk, Alain, Bubendorf, Lukas, Chung, Jin-Haeng, Hwang, David, Lin, Dongmei, Longshore, John, Noguchi, Masayuki, Rekhtman, Natasha, Sholl, Lynette, Travis, William, Yoshida, Akihiko, Wynes, Murry W, Wistuba, Ignacio I, Kerr, Keith M, Lantuejoul, Sylvie

“…Programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) is required to determine the eligibility for pembrolizumab monotherapy in advanced NSCLC worldwide…”
Get more information

Molecular Testing for Treatment of Metastatic Non‐Small Cell Lung Cancer: How to Implement Evidence‐Based Recommendations by Levy, Benjamin P., Chioda, Marc D., Herndon, Dana, Longshore, John W., Mohamed, Mohamed, Ou, Sai‐Hong Ignatius, Reynolds, Craig, Singh, Jaspal, Wistuba, Ignacio I., Bunn, Paul A., Hirsch, Fred R.

“…The recent discovery of relevant biomarkers has reshaped our approach to therapy selection for patients with non‐small cell lung cancer. The unprecedented…”
Get full text

Abstract 1394: RT-PCR and NGS comparison: detection of known EGFR mutations in non-small-cell lung cancer clinical samples with routine laboratory testing by Palma, John F., Tai, Yu Chuan, Liu, Wei-min, Anderson, Steve, Madan, Anup, Longshore, John W., Rao, Arundhati

“…Abstract Next-generation sequencing (NGS) promises to deliver clinical mutation analysis for multiple actionable biomarkers at once. However, most targeted…”
Get full text

BRAF p.V600E immunohistochemistry in challenging samples: about false-positive and false-negative results—reply by Fisher, Kevin E., MD, PhD, Cohen, Cynthia, MD, Palma, John F., PhD, Longshore, John W., PhD

“…[...]we encountered this pitfall numerous times in our study; nonspecific staining secondary to macrophages/histiocytes, and pigmented melanophages in…”
Get full text

Multiplex testing for Factor II and Factor V mutations in thrombophilia: technical verification and clinical validation of the cobas® Factor II and Factor V test by Longshore, John W., DeMartin, Kelli, Yu, Karen, Das, Partha, Zhang, Guili, Rehage, Taraneh Tamaddon, Jethwaney, Deepa, Karwowska, Sylwia

“…Laboratory testing for thrombophilia is complicated but essential for diagnosis. In 2017, the cobas ® Factor II and Factor V Test (cobas F2F5 test) was…”
Get full text

Tackling the implementation gap for the uptake of NGS and advanced molecular diagnostics into healthcare systems by Horgan, Denis, Van den Bulcke, Marc, Malapelle, Umberto, Troncone, Giancarlo, Normanno, Nicola, Capoluongo, Ettore D., Prelaj, Arsela, Rizzari, Carmelo, Trapani, Dario, Singh, Jaya, Kozaric, Marta, Longshore, John, Ottaviano, Manuel, Boccia, Stefania, Pravettoni, Gabriella, Cattaneo, Ivana, Malats, Núria, Buettner, Reinhard, Lekadir, Karim, de Lorenzo, Francesco, Hofman, Paul, De Maria, Ruggero

“…Next-generation sequencing (NGS) and liquid biopsy (LB) showed positive results in the fight against different cancer types. This paper aims to assess the…”
Get full text

Accelerating the Development and Validation of Liquid Biopsy for Early Cancer Screening and Treatment Tailoring by Horgan, Denis, Čufer, Tanja, Gatto, Francesco, Lugowska, Iwona, Verbanac, Donatella, Carvalho, Ângela, Lal, Jonathan A, Kozaric, Marta, Toomey, Sinead, Ivanov, Hristo Y, Longshore, John, Malapelle, Umberto, Hasenleithner, Samantha, Hofman, Paul, Alix-Panabières, Catherine

“…Liquid biopsy (LB) is a minimally invasive method which aims to detect circulating tumor-derived components in body fluids. It provides an alternative to…”
Get full text

American College of Medical Genetics Statement on Diagnostic Testing for Uniparental Disomy by Shaffer, Lisa G, Agan, Noelle, Goldberg, James D, Ledbetter, David H, Longshore, John W, Cassidy, Suzanne B

Get full text

A retrospective analysis of the clinical performance of human papillomavirus testing using SurePath sample collection by McDermott, James E., MD, Symanowski, James T., PhD, Livasy, Chad A., MD, Greger, Geraldine, CT(ASCP), Longshore, John W., PhD

“…Introduction We present a retrospective analysis of our high-risk human papillomavirus (hr-HPV) test performance using SurePath samples, and we compare these…”
Get full text